(+)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof
The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating of or preventing relapse of depression, anxiety disorders, eating disorders, or urinary incontinence in a patient comprising administering (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof. The (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (−)-enantiomer.
1. A method for treating an anxiety disorder in a patient, comprising administering to a patient in need of such treatment an effective amount of (+)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, each being substantially free of its corresponding (−)-enantiomer.
2. The method according to claim 1 , wherein (+)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof has no more than about 2% w/w of the corresponding (−)-enantiomer.
3. The method according to claim 1 , wherein the (+)-1-(3,4Dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof has no more than about 1% w/w of the corresponding (−)-enantiomer.
4. The method of claim 1 , wherein the anxiety disorder is selected from the group consisting of Panic Disorder, Panic Attack, Agoraphobia, Generalized Anxiety Disorder, Obsessive-Compulsive Disorders, Phobic Disorders and Post-Traumatic Stress Disorders.
5. The method of claim 2 , wherein the anxiety disorder is selected from the group consisting of Panic Disorder, Panic Attack, Agoraphobia, Generalized Anxiety Disorder, Obsessive-Compulsive Disorders, Phobic Disorders and Post-Traumatic Stress Disorders.
6. The method of claim 3 , wherein the anxiety disorder is selected from the group consisting of Panic Disorder, Panic Attack, Agoraphobia, Generalized Anxiety Disorder, Obsessive-Compulsive Disorders, Phobic Disorders and Post-Traumatic Stress Disorders.
7. A method for treating an eating disorder in a patient, comprising administering to a patient in need of such treatment an effective amount of (+)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane.
8. The method according to claim 7 , wherein the (+)-1-(3,4Dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof has no more than about 2% w/w of the corresponding (−)-enantiomer.
9. The method according to claim 7 , wherein the (+)-1-(3,4Dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof has no more than about 1% w/w of the corresponding (−)-enantiomer.
10. The method of claim 7 , wherein the eating disorder is selected from the group consisting of Anorexia Nervosa, Binge-Eating Disorder, Bulimia Nervosa—Nonpurging Type and Bulimia Nervosa—Purging Type.
11. The method of claim 8 , wherein the eating disorder is selected from the group consisting of Anorexia Nervosa, Binge-Eating Disorder; Bulimia Nervosa—Nonpurging Type and Bulimia Nervosa—Purging Type.
12. The method of claim 9 , wherein the eating disorder is selected from the group consisting of Anorexia Nervosa, Binge-Eating Disorder, Bulimia Nervosa—Nonpurging Type and Bulimia Nervosa—Purging Type.
13. A method for treating a urinary incontinence disorder in a patient, comprising administering to a patient in need of such treatment an effective amount of (+)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, each being substantially free of its corresponding (−)-enantiomer.
14. The method according to claim 13 , wherein the (+)-1-(3,4Dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof has no more than about 2% w/w of the corresponding (−)-enantiomer.
15. The method according to claim 13 , wherein the (+)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof has no more than about 1% w/w of the corresponding (−)-enantiomer.
16. The method of claim 13 , wherein the urinary incontinence disorder is selected from the group consisting of Urge Incontinence; Stress Incontinence, Overflow Incontinence, Functional Incontinence, Neurogenic Incontinence and Post-Prostatectomy Incontinence.
17. The method of claim 14 , wherein the urinary incontinence disorder is selected from the group consisting of Urge Incontinence, Stress Incontinence, Overflow Incontinence, Functional Incontinence, Neurogenic Incontinence and Post-Prostatectomy Incontinence.
18. The method of claim 15 , wherein the urinary incontinence disorder is selected from the group consisting of Urge Incontinence, Stress Incontinence, Overflow Incontinence, Functional Incontinence, Neurogenic Incontinence and Post-Prostatectomy Incontinence.